LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Lista de Ações・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Fechado

SetorSaúde

32.42 -6.03

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

32.26

Máximo

34.15

Indicadores-chave
By Trading Economics
Rendimento	-5M -128M
Vendas	6.8M 11M
EPS	-1.23
Margem de lucro	-1,191.029
Funcionários	594
EBITDA	-18M -139M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+155.33% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-469M 3.9B
Abertura anterior	38.45
Fecho anterior	32.42

Sentimento de Notícias

By Acuity

87%

13%

310 / 344 Ranking em Healthcare

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jun. de 2026, 20:30 UTC

Ganhos

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

2 de jun. de 2026, 23:58 UTC

Conversa de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 de jun. de 2026, 23:41 UTC

Conversa de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 de jun. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 de jun. de 2026, 22:57 UTC

Conversa de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 de jun. de 2026, 22:50 UTC

Conversa de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 de jun. de 2026, 21:00 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

2 de jun. de 2026, 20:46 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:38 UTC

Ganhos

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 de jun. de 2026, 20:21 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:12 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Product Rev $594M

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

155.33% parte superior

Previsão para 12 meses

Média 88.14 USD 155.33%

Máximo 97 USD

Mínimo 81 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

310 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.